- Home
- QCLS vs INTS Comparison
QCLS vs INTS Comparison
Compare QCLS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCLS
- INTS
- Stock Information
- Founded
- QCLS 2014
- INTS 2012
- Country
- QCLS United States
- INTS United States
- Employees
- QCLS N/A
- INTS N/A
- Industry
- QCLS Biotechnology: In Vitro & In Vivo Diagnostic Substances
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- QCLS Health Care
- INTS Health Care
- Exchange
- QCLS Nasdaq
- INTS Nasdaq
- Market Cap
- QCLS 12.5M
- INTS 12.2M
- IPO Year
- QCLS N/A
- INTS 2023
- Fundamental
- Price
- QCLS $3.80
- INTS $0.42
- Analyst Decision
- QCLS
- INTS Strong Buy
- Analyst Count
- QCLS 0
- INTS 4
- Target Price
- QCLS N/A
- INTS $4.50
- AVG Volume (30 Days)
- QCLS 820.0K
- INTS 87.5M
- Earning Date
- QCLS 11-19-2025
- INTS 11-06-2025
- Dividend Yield
- QCLS N/A
- INTS N/A
- EPS Growth
- QCLS N/A
- INTS N/A
- EPS
- QCLS N/A
- INTS N/A
- Revenue
- QCLS N/A
- INTS N/A
- Revenue This Year
- QCLS N/A
- INTS N/A
- Revenue Next Year
- QCLS N/A
- INTS N/A
- P/E Ratio
- QCLS N/A
- INTS N/A
- Revenue Growth
- QCLS N/A
- INTS N/A
- 52 Week Low
- QCLS $2.50
- INTS $0.19
- 52 Week High
- QCLS $164.00
- INTS $3.18
- Technical
- Relative Strength Index (RSI)
- QCLS N/A
- INTS 50.05
- Support Level
- QCLS N/A
- INTS $0.38
- Resistance Level
- QCLS N/A
- INTS $0.50
- Average True Range (ATR)
- QCLS 0.00
- INTS 0.07
- MACD
- QCLS 0.00
- INTS -0.02
- Stochastic Oscillator
- QCLS 0.00
- INTS 18.75
About QCLS Q/C Technologies Inc. Common Stock
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.